Categories
Blood Cancer

Current treatment options and emerging strategies in MCL [Video]

Manali Kamdar, MD, University of Colorado Cancer Center, Aurora, CO, provides an overview of the current treatment paradigm in mantle cell lymphoma (MCL) and outlines emerging therapeutic strategies for this disease. The treatment landscape of MCL has dramatically changed over the past few years with the advent of BTK inhibitors (BTKi) for patients who relapse after frontline therapy, as well as with the approval of brexucabtagene autoleucel (brexu-cel). Pirtobrutinib is now used for patients who relapse after BTKi. Nevertheless, there remains an unmet need for patients with high-risk disease as they have a suboptimal response to BTKi. CAR-T therapy has emerged as a promising alternative for those patients and lisocabtagene maraleucel (liso-cel) is currently being explored in a trial that has reported encouraging safety and efficacy results so far. Bispecific antibodies such as glofitamab are also being evaluated in R/R MCL. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

Categories
Blood Cancer

An overview of CAR-T therapy in DLBCL and MCL [Video]

Peter Riedell, MD, University of Chicago Medicine, Chicago, IL, comments on the key topics of a talk designed to provide oncologists and bone marrow transplant (BMT) specialists with an overview of CAR-T therapy in diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). The presentation recapitulated data on the three approved CAR-T products in DLBCL in the third-line setting, axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel), as well as data from the three pivotal trials comparing these CAR-T therapies to standard of care (SOC) in second line in DLBCL. Advances in MCL were also highlighted and included data showing the benefits of brexucabtagene autoleucel (brexu-cel) in these patients. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

Categories
Blood Cancer

Latest updates in CAR-T therapy for follicular lymphoma [Video]

Peter Riedell, MD, University of Chicago Medicine, Chicago, IL, provides an overview of recent advances in CAR-T therapy for follicular lymphoma (FL). Axicabtagene ciloleucel (axi-cel) was the first CAR-T therapy to be approved in FL. The promising results of the ZUMA-5 (NCT03105336) and ELARA (NCT03568461) studies are expected to lead to the approval of tisagenlecleucel (tisa-cel) in relapsed/refractory (R/R) FL. Further longitudinal data is required to better understand the impact of CAR-T therapy in patients with FL, as well as to determine which patients are most likely to benefit from this immunotherapy. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

Categories
Blood Cancer

Current indications for the use of brentuximab vedotin in Hodgkin lymphoma [Video]

Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, outlines the indications for brentuximab vedotin in Hodgkin lymphoma (HL) and comments on the management of brentuximab vedotin-induced peripheral sensory neuropathy. Brentuximab vedotin is currently used in a wide range of settings in HL, including frontline and consolidation therapy. Peripheral sensory neuropathy is a common side effect induced by brentuximab vedotin. Guidelines for the management of this adverse event recommend decreasing the drug dose or increasing the time interval between each dose. Patients who still experience neurotoxicity after this should stop using the drug definitively. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

Categories
Blood Cancer

The evolving treatment landscape of R/R LBCL [Video]

Manali Kamdar, MD, University of Colorado Cancer Center, Aurora, CO, comments on current and emerging immunotherapies for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). In recent years, a large number of agents have been approved, namely tafasitamab-lenalidomide, polatuzumab vedotin with rituximab and bendamustine, loncastuximab tesirine, and CAR-T therapy in both second and third-line therapy. In addition, multiple promising agents are currently under investigation. These include bispecific antibodies such as mosunetuzumab and glofitamab, and studies have reported high efficacy with a highly manageable toxicity profile in heavily pre-treated patients. In parallel, existing CAR-T constructs are being improved and new constructs targeting new antigens are being evaluated. There is also progress in the field of R/R Hodgkin lymphoma, where CD30-directed CAR-Ts co-expressing CCR4 have shown encouraging results. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

Categories
Blood Cancer

Advances & unmet needs in APL [Video]

Firas El Chaer, MD, University of Virginia, Charlottesville, VA, comments on recent advances in acute promyelocytic leukemia (APL), highlighting remaining unmet needs in this field. Dr El Chaer first talks on the benefits of substituting anthracycline with gemtuzumab ozogamicin in the induction regimen of high-risk APL patients, and switching intravenous arsenic trioxide to an oral-based regimen. Dr El Chaer further underlines the importance of educating people about the symptoms of APL, as early ATRA treatment is critical to increase the chance of curing a patient. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

Categories
Blood Cancer

Cord blood transplantation vs MMUD with PTCy in AML [Video]

Bhagirathbhai Dholaria, MBBS, Vanderbilt University Medical Center, Nashville, TN, discusses the finding of a study comparing cord blood transplantation versus mismatched unrelated donor (MMUD) with post-transplant cyclophosphamide (PTCy) in patients with acute myeloid leukemia (AML). The study found that there was a higher rate of non-relapse mortality (NRM) and graft failure in cord blood transplant recipients compared to MMUD recipients. In addition, the study found that the risk of graft-versus-host disease (GvHD) was lower in MMUD recipients treated with PTCy. Overall, this study strongly supports the use of MMUD transplantation. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

Categories
Blood Cancer

Challenges in CAR-T therapy for myeloid malignancies [Video]

Bhagirathbhai Dholaria, MBBS, Vanderbilt University Medical Center, Nashville, TN, discusses some of the key obstacles to developing CAR-T therapies for myeloid malignancies. To being with, the most commonly expressed antigens in acute myeloid leukemia (AML) are also expressed on normal hematopoietic stem cells (HSCs), which can lead to off-target effects with CAR-T therapy. In addition, patients with myeloid malignancies have a poor immune microenvironment and have often received prior allogeneic transplantation. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

Categories
Blood Cancer

CARTITUDE-5: VRd + cilta-cel or Rd in newly diagnosed multiple myeloma [Video]

Saad Usmani, MD, MBA, FACP, Memorial Sloan Kettering Cancer Center, New York, NY, gives an update on the CARTITUDE-5 study (NCT04923893), which compares the efficacy of bortezomib, lenalidomide and dexamethasone (VRd) induction therapy followed by ciltacabtagene autoleucel (cilta-cel) or lenalidomide and dexamethasone maintenance (Rd) in patients with newly diagnosed multiple myeloma (NDMM) who are transplant-ineligible or that have deferred transplantation until first relapse. The primary endpoint is measurable residual disease (MRD) negativity and secondary endpoints include overall response rate (ORR) and overall survival (OS). The results from this trial are eagerly awaited and could potentially be practice-changing. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

Categories
Blood Cancer

autoHSCT as the best predictor for long-term survival in multiple myeloma [Video]

Guillermo José Ruiz-Argüelles, MD, FRCP, Universidad Popular Autónoma del Estado de Puebla, Puebla, Mexico, talks on the use of autologous hematopoietic stem cell transplantation (autoHSCT) to predict long-term survival in patients with multiple myeloma. A recent study conducted in Mexico demonstrated that autoHSCT was the best determinant of long-term survival irrespective of other characteristics of the disease. In addition, Prof. Ruiz-Argüelles explains that Latin American patients with multiple myeloma have a better prognosis than other populations. According to Prof. Ruiz-Argüelles, autoHSCT is the best available treatment for multiple myeloma. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

Categories
Blood Cancer

A look into the future of multiple myeloma treatment: T-cell redirecting therapies vs autoHSCT [Video]

In recent years, advances in T-cell redirecting therapies have started questioning the role of autologous hematopoietic stem cell transplantation (autoHSCT) in newly diagnosed multiple myeloma (NDMM). In this video, Saad Usmani, MD, MBA, FACP, Memorial Sloan Kettering Cancer Center, New York, NY, outlines some of his arguments in favour of autoSCT remaining the standard of care in multiple myeloma over the next five years. Dr Usmani explains that there is insufficient data about the long-term safety of T-cell redirecting therapies. In addition, the scalability of these novel T-cell redirecting therapies remains an issue as they are significantly more expensive than autoSCT. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

Categories
Blood Cancer

Exciting CAR-T data in multiple myeloma and follicular lymphoma: CARTITUDE-2, ELARA & ZUMA-5 [Video]

Dholaria Bhagirathbhai, MBBS, Vanderbilt University Medical Center, Nashville, TN, shares his thoughts on the most exciting data in CAR-T therapy that will be released at this year’s Tandem Meetings, including results from the CARTITUDE-2 (NCT04133636), ELARA (NCT03568461), and ZUMA-5 (NCT03105336) studies. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.